NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Review proposal of NICE guidance no. 82; pimecrolimus and tacrolimus for atopic eczema

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
 Manufacturers/sponsors Astellas Pharma (tacrolimus) Novartis Pharmaceuticals (pimecrolimus) Patient/carer groups Action Against Allergy Action for Sick Children Age Concern England Allergy UK Black Health Agency Changing Faces Chinese National Healthy Living Centre Confederation of Indian Organisations Counsel and Care Equalities National Council Help the Aged Muslim Council of Great Britain Muslim Health Network National Eczema Society Skin Care Campaign South Asian Health Foundation Specialised Healthcare Alliance 	 General Age Concern Cymru Board of Community Health Councils in Wales British National Formulary Department of Health, Social Services and Public Safety for Northern Ireland Medicines and Healthcare products Regulatory Agency (MHRA) National Public Health Service for Wales NHS Confederation NHS Purchasing and Supply Agency NHS Quality Improvement Scotland Scottish Medicines Consortium Comparator manufacturers Actavis (hydrocortisone) Alliance Pharmaceuticals (hydrocortisone) Astellas Pharma (hydrocortisone, hydrocortisone butyrate) BCM Specials (hydrocortisone) Bell Sons & Co. (hydrocortisone) Biorex Laboratories (hydrocortisone)
 WellChild Professional groups British Association for Services to the Elderly 	 Celltech (betamethasone valerate) Chemidex (hydrocortisone) Co-Pharma (hydrocortisone) Derma UK (fluocinolone acetonide, fluocinonide)

National Institute for Health and Clinical Excellence

Review proposal of NICE guidance no. 82 pimecrolimus and tacrolimus for atopic eczema

Issue Date: September 2007 Page 1 of 7

Consultees Commentators (no right to submit or appeal) Dermal Laboratories (hydrocortisone, **British Association of Dermatologists** British Dermatological Nursing Group betamethasone valerate) British Skin Foundation **Diomed Developments** (hydrocortisone) Community Practitioners and Health Fabre (clobetasol propionate) Visitors Association Galderma (hydrocortisone, clobetasol National Association of Primary Care propionate) Primary Care Dermatology Society Galpharm Healthcare (hydrocortisone) Royal College of General GlaxoSmithKline (hydrocortisone, **Practitioners** betamethasone valerate, clobetasone Royal College of Nursing butyrate, fluticasone propionate, Royal College of Paediatrics and clobetasol propionate) Child Health GP Pharma (fluocinolone acetonide, Royal College of Physicians fluocinonide) Royal Pharmaceutical Society Meadow Laboratories (fluocortolone, Roval Society of Medicine – diflucortolone valerate) Intellectual Disabilities Forum **Novartis Pharmaceuticals** United Kingdom Clinical Pharmacy (hydrocortisone) Association • Pliva Pharma (alclometasone dipropionate) Others Reckitt Benckiser Healthcare UK Department of Health (hydrocortisone) Westminster PCT Roussel Laboratories (hydrocortisone) Warrington PCT Sandoz Ltd (hydrocortisone) Welsh Assembly Government Schering Plough (betamethasone dipropionate, mometasone furoate) Teva Pharmaceutical Industries (hydrocortisone) • Thornton & Ross (hydrocortisone) Typharm (fludroxycortide) • UCB Pharma (betamethasone valerate) Waymade (hydrocortisone) Wockhardt UK (hydrocortisone)

Relevant research groups

- Cochrane Skin Group, Centre of Evidence-based Dermatology, University of Nottingham
- Policy Research Institute on Ageing and Ethnicity
- Skin Research Centre
- Skin Treatment & Research Trust

Page 2 of 7

National Institute for Health and Clinical Excellence

Review proposal of NICE guidance no. 82 pimecrolimus and tacrolimus for atopic eczema

Issue Date: September 2007

APPENDIX A

Consultees	Commentators (no right to submit or appeal)
	The British Epidermo-Epidemiology Society
	 Assessment team Assessment group tbc National Coordinating Centre for Health Technology Assessment
	 Associated Guideline Groups National Collaborating Centre for Women and Children
	Associated Public Health Groups • (None)

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Clinical Excellence

Review proposal of NICE guidance no. 82 pimecrolimus and tacrolimus for atopic eczema

Issue Date: September 2007 Page 3 of 7

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

National Institute for Health and Clinical Excellence

Review proposal of NICE guidance no. 82 pimecrolimus and tacrolimus for atopic eczema

Issue Date: September 2007 Page 4 of 7

Manufacturer table

The matrix lists the manufacturers who have been invited to participate in a technology appraisal. As an appraisal progresses the matrix may not necessarily list all the relevant products relating to it (as manufacturers may decide that they do not wish to be involved). This table has been produced to capture all the related products for easy identification of interests for anyone involved in the topic.

Consultees		
Manufacturer	Generic Name	
Astellas Pharma Inc.	tacrolimus	
Novartis Pharmaceuticals UK Ltd	pimecrolimus	
Commentators		
Manufacturer	Generic Name	
Actavis	hydrocortisone	
Astellas	hydrocortisone, hydrocortisone butyrate	
BCM Specials	hydrocortisone	

National Institute for Health and Clinical Excellence

Review proposal of NICE guidance no. 82 pimecrolimus and tacrolimus for atopic eczema

Issue Date: September 2007 Page 5 of 7

Bell Sons & Co.	hydrocortisone
Biorex Laboratories	hydrocortisone
Celltech	betamethasone valerate
Co-Pharma	hydrocortisone
Derma UK	fluocinolone acetonide, fluocinonide
Dermal	hydrocortisone, betamethasone
	valerate
Diomed Pharmaceuticals	hydrocortisone
Dowelhurst Ltd	betamethasone valerate
Galpharm Healthcare	hydrocortisone
GlaxoSmithKline	hydrocortisone, betamethasone
	valerate, clobetasone butyrate,
	fluticasone propionate, clobetasol
	propionate
Meadow Laboratories	fluocortolone, diflucortolone valerate
Novartis Pharmaceuticals Ltd	hydrocortisone, hydrocortisone generic
Pliva Pharma	alclometasone dipropionate
Reckitt Benckiser Healthcare UK	hydrocortisone
Roussel Laboratories	hydrocortisone
Sandoz Ltd	hydrocortisone
Schering Plough	betamethasone dipropionate,

National Institute for Health and Clinical Excellence

Review proposal of NICE guidance no. 82 pimecrolimus and tacrolimus for atopic eczema

Issue Date: September 2007 Page 6 of 7

APPENDIX A

	mometasone furoate
Teva Pharmaceutical Industries Ltd	hydrocortisone
Thornton & Ross	hydrocortisone
Typharm	fludroxycortide
UCB Pharma	betamethasone valerate
Waymade	hydrocortisone
Wockhardt UK Ltd	hydrocortisone generic

Issue Date: September 2007 Page 7 of 7